Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.61 |
| ▸ | DRD3 | P35462 | 3/20 | 0.61 |
| ▸ | DRD2 | P14416 | 8/20 | 0.53 |
| ▸ | HTR2C | P28335 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85231 | 0.91 | HTR2A (0.58) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL84998 | 0.88 | HTR2A (0.48) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL84575 | 0.88 | HTR2A (0.58) | HTR2ADRD3DRD2HTR7KCNH2 | |
| SCHEMBL85223 | 0.87 | DRD2 (0.55) | HTR2ADRD2HTR2CHTR7KCNH2 | |
| SCHEMBL85000 | 0.83 | HTR2A (0.61) | HTR2ADRD3DRD2HTR7KCNH2 | |
| SCHEMBL85045 | 0.81 | HTR2A (0.52) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL2733202 | 0.80 | HTR2C (0.51) | HTR2ADRD2HTR2CHTR7 | |
| SCHEMBL84567 | 0.78 | HTR2A (0.55) | HTR2ADRD3DRD2HTR7KCNH2 | |
| SCHEMBL605203 | 0.78 | HTR2A (0.74) | HTR2ADRD3 | |
| SCHEMBL19957359 | 0.77 | DRD2 (0.66) | HTR2ADRD3DRD2HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129410-B2 | Sleep maintenance insomnia; circadian rhythm abnormalities; side effect reduction | HYPNION, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | HYPNION, INC. | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214539-A1 | Benzisoxazole Piperidine Compounds and Methods of Use Thereof | GABRA5, GABRE, HCRTR2 | HTR2A 284/4885DRD3 994/4885DRD2 1344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.